Polo-like Kinase 4 inhibition: A strategy for cancer therapy?

Andrew J. Holland; Don W. Cleveland

doi:10.1016/j.ccr.2014.07.017

Polo-like Kinase 4 inhibition: A strategy for cancer therapy?

Andrew J. Holland
, Don W. Cleveland

School of Medicine

Research output: Contribution to journal › Short survey › peer-review

30 Scopus citations

Abstract

In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.

Original language	English (US)
Pages (from-to)	151-153
Number of pages	3
Journal	Cancer cell
Volume	26
Issue number	2
DOIs	https://doi.org/10.1016/j.ccr.2014.07.017
State	Published - Aug 11 2014

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ccr.2014.07.017

Cite this

@article{5270f2f3e020401184760515d9c8347e,

title = "Polo-like Kinase 4 inhibition: A strategy for cancer therapy?",

abstract = "In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.",

author = "Holland, \{Andrew J.\} and Cleveland, \{Don W.\}",

note = "Funding Information: We apologize to colleagues whose work was not discussed or cited owing to space constraints. Kevin Clutario is gratefully acknowledged for help preparing the figures. A.J.H. is funded by a Leukemia \& Lymphoma Society special fellowship, Leukemia Research Foundation Research Grant, W.W. Smith Charitable Trust Research Grant, March of Dimes Basil O{\textquoteright}Conner Scholar Award, Pew Scholar Award, and a Kimmel Scholar Award. D.W.C. is funded by a grant (R01-GM29513) from the NIH and receives salary support from the Ludwig Institute for Cancer Research.",

year = "2014",

month = aug,

day = "11",

doi = "10.1016/j.ccr.2014.07.017",

language = "English (US)",

volume = "26",

pages = "151--153",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Polo-like Kinase 4 inhibition

T2 - A strategy for cancer therapy?

AU - Holland, Andrew J.

AU - Cleveland, Don W.

N1 - Funding Information: We apologize to colleagues whose work was not discussed or cited owing to space constraints. Kevin Clutario is gratefully acknowledged for help preparing the figures. A.J.H. is funded by a Leukemia & Lymphoma Society special fellowship, Leukemia Research Foundation Research Grant, W.W. Smith Charitable Trust Research Grant, March of Dimes Basil O’Conner Scholar Award, Pew Scholar Award, and a Kimmel Scholar Award. D.W.C. is funded by a grant (R01-GM29513) from the NIH and receives salary support from the Ludwig Institute for Cancer Research.

PY - 2014/8/11

Y1 - 2014/8/11

N2 - In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.

AB - In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.

UR - https://www.scopus.com/pages/publications/84905690496

UR - https://www.scopus.com/pages/publications/84905690496#tab=citedBy

U2 - 10.1016/j.ccr.2014.07.017

DO - 10.1016/j.ccr.2014.07.017

M3 - Short survey

C2 - 25117704

AN - SCOPUS:84905690496

SN - 1535-6108

VL - 26

SP - 151

EP - 153

JO - Cancer cell

JF - Cancer cell

IS - 2

ER -

Polo-like Kinase 4 inhibition: A strategy for cancer therapy?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this